David Jin - 01 Apr 2026 Form 4 Insider Report for Fortress Biotech, Inc. (FBIO)

Reporting relationship: Chief Financial Officer
Issuer ticker: FBIO
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2026, 16:05:13 UTC
Prior SEC filing: 30 Dec 2025
Next SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ David Jin

Key filing fact

David Jin filed Form 4 for Fortress Biotech, Inc. (FBIO) on 01 Apr 2026.

Key facts

This page summarizes David Jin's Form 4 filing for Fortress Biotech, Inc. (FBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Apr 2026, 16:05.

Change

Previous filing in this sequence was filed on 30 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001930732 Primary reporting owner

Jin David

Relationship: Chief Financial Officer
Address: C/O FORTRESS BIOTECH, INC., 1111 KANE CONCOURSE SUITE 301, BAY HARBOR ISLANDS
Signature: /s/ David Jin
Signature date: 01 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FBIO transaction

Common Stock, par value $0.001

Award

Transaction value
Shares: +2,967
Change %: +0.24%
Price: $2.18^*
Shares after: 1,251,571
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Footnote F2

Total holdings include 1,230,000 shares underlying deferred restricted stock units.